The New Scientific Power: The Role of Philanthropy, Patient Advocates, and Other Novel Partners in Changing our Medical Future at The 2007 Aspen Health Forum.
Increasingly, philanthropic dollars are supporting medical science research and efforts to eradicate diseases, patient advocates are pressing for the reallocation of resources, and novel partnerships are making new ventures possible through shared risk- Aspen Institute
Susan Dentzer is Senior Policy Adviser for the Robert Wood Johnson Foundation.
Scott Johnson, who has been living with multiple sclerosis for 34 years, is using his acumen as a business consultant and serial entrepreneur to reform a system for medical research and drug development that has failed to produce new patient treatments for millions living with chronic and debilitating diseases.
Featured in Fortune (September 2006) as a "lifesaving shakeup in the world of medical research," Johnson's big idea has since delivered on that promise by (1) proving that basic science can be accelerated and (2) creating connections between academic scientists and those who commercially develop drugs. This will mean the faster development and delivery of patient treatments and cures.
Richard D. Klausner is Managing Partner of The Column Group, a venture capital fund focused on building the next generation of drug discovery and development companies. Dr. Klausner is the former Executive Director for Global Health of the Bill and Melinda Gates Foundation. Prior to that he served as Director of the National Cancer Institute from 1995 to 2001.
Dr. Klausner's research in hematology has been recognized with many awards, including the William Damashek Prize and the Outstanding Investigator Award of the American Federation of Clinical Research. He has served as an adviser to the Presidents of the National Academies for counter-terrorism and as a liaison to the White House Office of Science and Technology Policy. Dr. Klausner is a member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences.
Robert N. Klein's commitment to advancing medical research originated in his younger son Jordan's diagnosis with Juvenile Diabetes in 2001. In addition, his mother was diagnosed with Alzheimer's two years earlier. In 2002, Klein was a principal negotiator, as a part of a Juvenile Diabetes Research Foundation patient advocate team that worked successfully to pass a $1.5 billion mandatory federal funding bill for an additional five years of Type 1 and Type 2 diabetes supplemental National Institutes of Health research funding.
In 2003, Klein served as the author and Chairman of California's Proposition 71, the $6 billion "California Stem Cell Research and Cures" ballot initiative. Currently he serves as the Chairman of the Governing Board of the California Institute of Regenerative Medicine established by Proposition 71 to manage the peer review, standards, and grant process for the $3 billion in stem cell research funding authorized by the proposed Initiative.
Hala Moddelmog is President and Chief Executive Officer of Susan G. Komen for the Cure, which she joined in September 2006. As CEO, she is responsible for all aspects of the organization's management and works closely with Komen for the Cure volunteers, staff and the board of directors. A five-year breast cancer survivor, she previously served as Founder and CEO of Catalytic Ventures, a private equity firm that consulted and invested in the food service industry.
She was the first woman in corporate America to lead an international QSR brand (quick service restaurant) in 1995 when she was named president of Church's Chicken, a division of Atlanta-based AFC Enterprises. She subsequently led Church's to record sales and profit performance. She also held executive management and marketing positions at Church's Chicken, Arby's Franchise Association and BellSouth. Ms. Moddelmog holds a master's degree in journalism and mass communications from the University of Georgia.
Amy McGuire Porter
Amy McGuire Porter is Executive Director of the Foundation for the National Institutes of Health, a position she has held since 2001. Prior to that she was its director of development. Under Ms. Porter's leadership, the foundation's portfolio of programs has grown to some 50 programs currently under its management and supported by about $400 million generated from private contributions. The foundation is a global leader in the creation of specially configured, high-impact, public-private partnerships in biomedical research.
Prior to joining the foundation, Ms. Porter served as director of development of the National AIDS Fund, an organization dedicated to reducing the impact of HIV/AIDS in America’s communities. Previously, she also was national director of development for Volunteers of America, a national nonprofit organization that provides health and human service programs to 1.5 million people across the United States each year. Ms. Porter is a graduate of Kent State University.